Associations between glutathione S-transferase π Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy

Cancer Epidemiology

Volumn 34, Issue 2, 2010, Pages 189-193

  Kanai, Masashi ^a   Yoshioka, Akira ^b   Tanaka, Shiro ^a   Nagayama, Satoshi ^a   Matsumoto, Shigemi ^a   Nishimura, Takafumi ^a   Niimi, Miyuki ^a   Teramukai, Satoshi ^a   Takahashi, Ryo ^a   Mori, Yukiko ^a   Kitano, Toshiyuki ^a   Ishiguro, Hiroshi ^a   Yanagihara, Kazuhiro ^a   Chiba, Tsutomu ^a   Fukushima, Masanori ^a   Matsuda, Fumihiko ^c  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b MITSUBISHI KYOTO HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

AGXT Ile340Met; AGXT Pro11Leu; Colorectal cancer; GSTP1 Ile105Val; Neurotoxicity; Oxaliplatin

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE T1; GLYCINE AMINOTRANSFERASE; ISOLEUCINE; LEUCINE; METHIONINE; OXALIPLATIN; PROLINE; VALINE; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; GLUTATHIONE TRANSFERASE P1; GLYOXYLATE AMINOTRANSFERASE; PLATINUM COMPLEX;

ADULT; AGED; ALLELE; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG INDUCED DISEASE; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; NEUROLOGIC DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; TRANSAMINASES;

EID: 77950299964     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.02.008     Document Type: Article

References (40)

1. de Gramont A., Vignoud J., Tournigand C., Louvet C., Andre T., Varette C., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33 (1997) 214-219
2. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
3. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
4. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
5. Nordlinger B., Sorbye H., Glimelius B., Poston G.J., Schlag P.M., Rougier P., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008) 1007-1016
6. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30 (2003) 5-13
7. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5 Suppl. 1 (2005) S38-S46
8. Graham J., Mushin M., and Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov 3 (2004) 11-12
9. Land S.R., Kopec J.A., Cecchini R.S., Ganz P.A., Wieand H.S., and Colangelo L.H. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25 (2007) 2205-2211
10. Ishimoto T.M., and Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12 (2002) 543-553
11. Zimniak P., Nanduri B., Pikula S., Bandorowicz-Pikula J., Singhal S.S., Srivastava S.K., et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 224 (1994) 893-899
12. Ali-Osman F., Akande O., Antoun G., Mao J.X., and Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272 (1997) 10004-10012
13. Watson M.A., Stewart R.K., Smith G.B., Massey T.E., and Bell D.A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19 (1998) 275-280
14. Stoehlmacher J., Park D.J., Zhang W., Groshen S., Tsao-Wei D.D., Yu M.C., et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94 (2002) 936-942
15. Stoehlmacher J., Park D.J., Zhang W., Yang D., Groshen S., and Zahedy S. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91 (2004) 344-354
16. Booton R., Ward T., Heighway J., Ashcroft L., Morris J., and Thatcher N. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol 1 (2006) 679-683
17. 105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12 (2006) 3050-3056
18. Ruzzo A., Graziano F., Kawakami K., Watanabe G., Santini D., Catalano V., et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24 (2006) 1883-1891
19. Goekkurt E., Hoehn S., Wolschke C., Wittmer C., Stueber C., Hossfeld D.K., et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer 94 (2006) 281-286
20. Oldenburg J., Kraggerud S.M., Cvancarova M., Lothe R.A., and Fossa S.D. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol 25 (2007) 708-714
21. Ruzzo A., Graziano F., Kawakami K., Watanabe G., Santini D., Catalano V., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25 (2007) 1247-1254
22. Marsh S., Paul J., King C.R., Gifford G., McLeod H.L., and Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25 (2007) 4528-4535
23. 105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8 (2007) 1693-1703
24. Gamelin L., Capitain O., Morel A., Dumont A., Traore S., Anne le B., et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 13 (2007) 6359-6368
25. Pare L., Marcuello E., Altes A., del Rio E., Sedano L., Salazar J., et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 99 (2008) 1050-1055
26. Kweekel D.M., Gelderblom H., Antonini N.F., Van der Straaten T., Nortier J.W., Punt C.J., et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 45 (2009) 572-578
27. Goekkurt E., Al-Batran S.E., Hartmann J.T., Mogck U., Schuch G., Kramer M., et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 27 (2009) 2863-2873
28. Grothey A., McLeod H.L., Green E.M., Sargent D.J., Fuchs C., Ramanathan R.K., et al. Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. J Clin Oncol 23 (2005) 3509
29. Adelsberger H., Quasthoff S., Grosskreutz J., Lepier A., Eckel F., and Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406 (2000) 25-32
30. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., and Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85 (2001) 2293-2297
31. Holmes R.P., and Assimos D.G. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. J Urol 160 (1998) 1617-1624
32. Innocenti F., Undevia S.D., Iyer L., Chen P.X., Das S., Kocherginsky M., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 (2004) 1382-1388
33. Han J.Y., Lim H.S., Shin E.S., Yoo Y.K., Park Y.H., Lee J.E., et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24 (2006) 2237-2244
34. Minami H., Sai K., Saeki M., Saito Y., Ozawa S., Suzuki K., et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17 (2007) 497-504
35. Cheeseman S.L., Joel S.P., Chester J.D., Wilson G., Dent J.T., and Richards F.J. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87 (2002) 393-399
36. Levi F., Perpoint B., Garufi C., Focan C., Chollet P., Depres-Brummer P., et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29A (1993) 1280-1284
37. Kurata S., Kanagawa T., Yamada K., Torimura M., Yokomaku T., Kamagata Y., et al. Fluorescent quenching-based quantitative detection of specific DNA/RNA using a BODIPY((R)) FL-labeled probe or primer. Nucleic Acids Res 29 (2001) E34
38. Matsumoto N., Kakihara F., Kimura S., Kurebayashi Y., Hirai M., Yohda M., et al. Single nucleotide polymorphism genotyping of CYP2C19 using a new automated system. Anal Biochem 370 (2007) 121-123
39. Kamatani N., Sekine A., Kitamoto T., Iida A., Saito S., Kogame A., et al. Large-scale single-nucleotide polymorphism (SNP) and haplotype analyses, using dense SNP maps, of 199 drug-related genes in 752 subjects: the analysis of the association between uncommon SNPs within haplotype blocks and the haplotypes constructed with haplotype-tagging SNPs. Am J Hum Genet 75 (2004) 190-203
40. Levi F., Zidani R., and Misset J. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350 (1997) 681-686